Effepharm acquired two bio-pharmaceutical companies recently, named Dendrimer Co. and Folvo Co., the acquisition has significantly enhanced our R&D capability in anti-aging and energy metabolism. Also Effepharm’s new R&D center is established.
Effepharm’s new R&D center will focus on new pharmaceutical and dietary ingredient development by means of plant extraction, fermentation and synthesis, etc. It is expected to open in Mar 2020 with more than 1400 square meters and a total investment of over 5 million USD. Besides facilitating new instruments and equipments, the R&D center will include 2 conference rooms, which will be used for training the customers as well as general public.
Effepharm is thrilled to tell you the big news. And the news is reported by Businesswire and other newspapers. For more information, visit